Capitalist venture

Patents are of paramount importance to the pharmaceutical industry. At the discovery program level, chemotype patentability is one of the key requirements for continued work on a particular structural class. Decisions by venture capitalists to fund startup companies are based, in part, on the strength of their patent portfolios. The presence or absence of a single key patent can determine the future of even the largest pharmaceutical company. Patents thus are a critical, inseparable component of the drug discovery process. 

Genentech was founded in 1976 by scientist Herbert Boyer and the venture capitalist Robert Swanson. Headquartered in San Francisco, it employs almost 5000 staff worldwide and has 10 protein-based products on the market. These include hGHs (Nutropin, Chapter 11), the anti-body-based products Herceptin and Rituxan (Chapter 13) and the thrombolytic agents Ac-tivase and TNKase (Chapter 12). The company also has 20 or so products in clinical trials. In 2004, it generated some US 4.6 billion in revenues. 

Subsequent rocketing oil and natural gas prices along with the concomitant action of venture capitalists changed all that. The price of energy and of traditional raw materials suddenly multiplied by a factor three or more. The route to innovative companies in the chemical industry is now open again. 

Looking to invest in rapidly growing sectors, venture capitalists have wisely funded the first sol-gel start-ups that are now conquering the markets remarkably, some of these venture funds are publicly (government) owned as in the case of Canada s SiliCycle. No matter whether private or public, these investments caused the rapid launch on the market of sol-gel functional silicas. 

Money attracts money. By far, the best endorsements for attracting new investors are the financial commitments of professional investors who have made noteworthy fortunes in the biotech arena. Usually, these are venture capitalists who have learned to judge entrepreneurs and their stories, or at least have been very lucky. Herein lies one of the main reasons for invihng high priced VC money into your deal it is a very good investment for attrachng more OEM in subsequent funding rounds. 

It is well known in the world of independent ventures that there often comes a point at which the founding team needs to be replaced by managers with different qualities. Indeed, one of the ways in which venture capitalists claim they add value is in provoking these transitions and helping locate relevant managerial talent. The same applies to many key people working within a corporate venture those with the right skills to function well when the task is discovery and creation are not necessarily able to make the transition to the tasks of enhancement and operational excellence. Moore (1991) terms this transition the transition from pioneers to settlers. As he describes (1991, p. 199) ... 

Green venture capitalist extraordinaire Vinod Khosla, a founder of Sun Microsystems, writes of one particular method for biofuels ... 

The age of biotechnology started in the USA with the foundation of the first biotech company. Genentech was founded by the renowned biochemist Herbert Boyer and the young visionary venture capitalist Robert Swanson. (Of the... 

Fourth, committing the funds needed to make current vaccines available to all who need them at a profit for the patent holders is a much more persuasive way to show venture capitalists, biotech firms, and multinational corporations that a market for diseases of the poor exists, than promising to buy a future vaccine without paying researchers or developers a dime until they have taken all the risks of failure and fully tested a yet-to-be-discovered vaccine many years from now. 

This condensation step should be taken a step further in the preparation of an elevator pitch. Imagine you are riding in an elevator with a famous venture capitalist (VC). You have one minute to interest this person in your idea before the elevator door opens. What would you say Probably you need to tell the VC the following ... 

Many venture capitalists like to see a billion-dollar market before backing a technology idea, and perhaps your TOA doesn t add up to something that sizable. Perhaps you have undervalued the potential for growth of the market, or perhaps you have ignored market segments that could add up to sufficient size. 

Genentech, Inc. was founded in by venture capitalist Robert A. Swanson and biochemist Dr. Heibert W. Boyer. In the early 1970s, Boyer and geneticist Stanley Colien pioneered a new scientific field called recombinant DNA technology. 

Land purchases and many of the costs associated with facility development can be accomplished with long-term loans of 15 to 30 years. Equipment such as pumps and trucks are usually depreciated over a few years and are funded with shorter-term loans. Operating expenses for such items as feed, chemicals, fuel, utilities, salaries, taxes, and insurance may require periodic short-term loans to keep the business solvent. The projected income should be based on a realistic estimate of farmgate value of the product and an accurate assessment of anticipated production. Each business plan should project income and expenses projected over the term of all loans in order to demonstrate to the lending agency or venture capitalist that there is a high probability the investment will be repaid. 

It takes too long and takes too much money. You can get a few of them to do it, but it is not a venture capitalist s normal undertaking. Today, biotech and information technologies are fundable but not materials science. I can guarantee it. Somebody needs to fund materials science because in many ways materials are the basis of all the technologies that follow. 

Venture capitalists Equity Can be large amounts Hard to find, share ownership... 

Many large companies find it difficult to manage these competency-building activities, and many have closed down their corporate laboratories, as discussed in Section B, 1.1.1.1. Hence, these competencies are often developed in smaller, start up companies sponsored by venture capitalists. These start up businesses then license... 

---